ROCKVILLE, Md. & SAN DIEGO--(BUSINESS WIRE)--Jan. 12, 2015-- Lockheed Martin (NYSE: LMT) and Illumina, Inc. (NASDAQ: ILMN) today announced a new strategic alliance to collaborate on scalable and affordable genomics solutions to provide personalized health care for national populations.
Genomics is the science of studying genomes or DNA. Applied to health care, analyzing a person’s DNA sequence data can provide a better understanding of health risks (such as how susceptible a person is to a particular disease or if the person may react to a type of medication), resulting in more precise and proactive medicine. By aggregating genomic data across large populations, public health and wellness officials can more effectively address health concerns, reducing health care costs and improving quality of life.
The alliance brings together Illumina’s next-generation genetic sequencing tools with Lockheed Martin’s expertise in large-scale information systems and integration to meet the needs of countries as they begin to integrate genomics into their national health systems.
“Genomics is enabling a fundamental transformation of health care,” said Horace Blackman, vice president of Health & Life Sciences for Lockheed Martin’s Information Systems & Global Solutions business. “We envision the advantages of early national adoption for countries across the globe, applying clinical decision support applications that can improve health and health care, and lower national health care costs.”
“We look forward to working with Lockheed Martin and global health care leaders as we develop best-in-class solutions to realize the full potential of nation-scale sequencing,” said Jay Flatley, Chief Executive Officer of Illumina. “We are excited about this collaboration, given the breadth and depth of Lockheed Martin’s operations and strategic relationships around the globe.”
About Lockheed Martin
Headquartered in Bethesda, Maryland, Lockheed Martin is a global security and aerospace company that employs approximately 113,000 people worldwide and is principally engaged in the research, design, development, manufacture, integration and sustainment of advanced technology systems, products and services. The Corporation’s net sales for 2013 were $45.4 billion.
About Illumina
Illumina is transforming human health as the global leader in sequencing and array-based technologies. The company serves customers in a broad range of markets, enabling the adoption of genomic solutions in research and clinical settings. To learn how Illumina is unlocking the power of the genome, visit www.illumina.com and follow @illumina.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150112006334/en/
Source: Illumina, Inc.
For Lockheed Martin:
Shayla Gibson, (301) 640-3162
shayla.v.gibson@lmco.com
or
For Illumina:
Jennifer Temple, (858) 882-6822
pr@illumina.com
or
For additional information, visit:
www.lockheedmartin.com/healthcare
